Dr Steve Daley, expert immunologist with QUT’s Centre for Immunology and Infection Control is the co-founding scientist at Resseptor Therapeutics, a new Australian biotech company which has launched with an initial AU$2.25 million investment to develop new therapies targeting autoimmune diseases and cancer.
Resseptor aims to develop new therapies for inflammatory conditions based on novel technology that improves the way our immune system recognises and responds to tissues, malignancy, and pathogens. Crucial discoveries were made by a multidisciplinary team of researchers during their tenure at Monash University, with the core intellectual property licensed to Resseptor by Monash Innovation. The founding team is based across Monash University, La Trobe University and QUT.